Adrián M. O.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase 3 Randomized Double‑Blind Trial of Orelabrutinib Combined with Rituximab and Bendamustine versus Rituximab‑Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma
- Efficacy Evaluation of Acalabrutinib, Venetoclax, and Rituximab in Treatment-Naïve Mantle Cell Lymphoma: A Phase II Multicenter Open-Label Study
- Tailored Ibrutinib and Venetoclax Regimens in Untreated Chronic Lymphocytic Leukemia: A Multicohort Efficacy Evaluation
Data & Insights
Has run more than one trial at 141 of 312 partner sites.
Specializations
Lymphoid Malignancies
This investigator specializes in treating various forms of lymphoid cancers, with particular emphasis on B-cell lymphomas and leukemia.
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Diffuse Large B-cell Lymphoma
The investigator's work encompasses both newly diagnosed and treatment-resistant cases.
Indolent Lymphomas
Focused on developing therapeutic approaches for slow-growing lymphomas, particularly follicular lymphoma and marginal zone lymphoma.
- Previously Untreated Follicular Lymphoma
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma
The research encompasses both initial treatment strategies and management of relapsed cases.
Novel Therapeutic Approaches
Investigating innovative treatment combinations incorporating targeted therapies and immunotherapy for hematologic malignancies.
- Antibody-Based Therapies
- Fixed-Duration Treatment Protocols
- MRD-Guided Therapy
The focus includes evaluating treatment duration optimization and response-adapted approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.